Simone Verhaar1, Pauline A J Vissers2, Huub Maas3, Lonneke V van de Poll-Franse2, Felice N van Erning4, Floortje Mols2. 1. TweeSteden Hospital, Department of Geriatrics, Tilburg, The Netherlands. Electronic address: simoneverhaar@hotmail.nl. 2. CoRPS - Center of Research on Psychology in Somatic diseases, Department of Medical and Clinical Psychology, Tilburg University, The Netherlands; Comprehensive Cancer Centre The Netherlands, Eindhoven Cancer Registry, The Netherlands. 3. TweeSteden Hospital, Department of Geriatrics, Tilburg, The Netherlands. 4. Comprehensive Cancer Centre The Netherlands, Eindhoven Cancer Registry, The Netherlands.
Abstract
BACKGROUND: The goal of this study was to compare health related quality of life (HRQoL) and disease-specific symptoms between colon cancer patients treated with surgery only (SU) and surgery and adjuvant chemotherapy (SU+adjCT). Results were stratified for those aged <70 and ⩾70years. HRQoL of patients was also compared with an age- and sex-matched normative population. METHODS: Patients diagnosed with colon cancer between January 2000 and June 2009, as registered within the population-based Eindhoven Cancer Registry, received a questionnaire on HRQoL (European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire version 3.0 (QLQ-C30)) and disease-specific symptoms (EORTC QLQ-Colorectal 38 (EORTC QLQ-CR38)) in 2010. The first was also completed by the normative population (n=685). RESULTS: 1606 (72%) colon cancer survivors responded to our questionnaire. 1542 colon cancer patients treated with SU (n=1031) or SU+adjCT (n=493) were included in this study. In colon cancer patients aged <70years and aged ⩾70 no statistical significant differences on the subscales of the EORTC QLQ-C30 or the EORTC QLQ-CR38 were observed between patients treated with SU and SU+adjCT. Colon cancer patients aged <70years either treated with SU or SU+adjCT reported significantly more insomnia, diarrhoea and financial problems compared with the normative population. No differences in HRQoL were found between colon cancer patients aged ⩾70years either treated with SU or SU+adjCT and the normative population. CONCLUSION: No differences in HRQoL and disease-specific symptoms were found between patients treated with SU versus SU+adjCT in both younger and elderly colon cancer patients. Withholding patients adjCT, based on concerns for long-term HRQoL or disease-specific symptoms does therefore not seem plausible.
BACKGROUND: The goal of this study was to compare health related quality of life (HRQoL) and disease-specific symptoms between colon cancerpatients treated with surgery only (SU) and surgery and adjuvant chemotherapy (SU+adjCT). Results were stratified for those aged <70 and ⩾70years. HRQoL of patients was also compared with an age- and sex-matched normative population. METHODS:Patients diagnosed with colon cancer between January 2000 and June 2009, as registered within the population-based Eindhoven Cancer Registry, received a questionnaire on HRQoL (European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire version 3.0 (QLQ-C30)) and disease-specific symptoms (EORTC QLQ-Colorectal 38 (EORTC QLQ-CR38)) in 2010. The first was also completed by the normative population (n=685). RESULTS: 1606 (72%) colon cancer survivors responded to our questionnaire. 1542 colon cancerpatients treated with SU (n=1031) or SU+adjCT (n=493) were included in this study. In colon cancerpatients aged <70years and aged ⩾70 no statistical significant differences on the subscales of the EORTC QLQ-C30 or the EORTC QLQ-CR38 were observed between patients treated with SU and SU+adjCT. Colon cancerpatients aged <70years either treated with SU or SU+adjCT reported significantly more insomnia, diarrhoea and financial problems compared with the normative population. No differences in HRQoL were found between colon cancerpatients aged ⩾70years either treated with SU or SU+adjCT and the normative population. CONCLUSION: No differences in HRQoL and disease-specific symptoms were found between patients treated with SU versus SU+adjCT in both younger and elderly colon cancerpatients. Withholding patients adjCT, based on concerns for long-term HRQoL or disease-specific symptoms does therefore not seem plausible.
Authors: Mohid S Khan; Thomas Walter; Amy Buchanan-Hughes; Emma Worthington; Lucie Keeber; Marion Feuilly; Enrique Grande Journal: World J Gastroenterol Date: 2020-08-14 Impact factor: 5.742